Ehnhage A, Rautiainen M, Fang A F, Sanchez S P
Department of Clinical Science, Intervention and Technology, Division of Otorhinolaryngology, Karolinska Institutet, and Nacka Närsjukhus Proxima AB, Stockholm, Sweden.
Int J Antimicrob Agents. 2008 Jun;31(6):561-6. doi: 10.1016/j.ijantimicag.2008.01.027. Epub 2008 May 5.
As high drug levels at the infection site are desirable for optimal activity, this study explored whether one dose of azithromycin extended release (AZ-ER) achieved higher azithromycin exposure in sinus fluid than azithromycin immediate release (AZ-IR) in adults with acute bacterial sinusitis. Subjects received AZ-ER (2g single dose; n=5) or AZ-IR (500mg daily for 3 days; n=4) and blood and sinus aspirates were collected until 120 h after initial dosing. Within 24 h, exposure was four- and three-fold higher with AZ-ER than with AZ-IR in serum and sinus fluid, respectively. Sinus fluid exposure was five- and three-fold higher than serum for AZ-IR and AZ-ER, respectively. Azithromycin concentrations in sinus fluid were maintained up to 120 h.
由于感染部位的高药物水平对于最佳活性是理想的,本研究探讨了在患有急性细菌性鼻窦炎的成年人中,一剂阿奇霉素缓释剂(AZ-ER)在鼻窦液中是否比阿奇霉素速释剂(AZ-IR)实现更高的阿奇霉素暴露量。受试者接受AZ-ER(单剂量2g;n = 5)或AZ-IR(每日500mg,共3天;n = 4),并在首次给药后直至120小时收集血液和鼻窦抽吸物。在24小时内,AZ-ER在血清和鼻窦液中的暴露量分别比AZ-IR高4倍和3倍。对于AZ-IR和AZ-ER,鼻窦液暴露量分别比血清高5倍和3倍。鼻窦液中的阿奇霉素浓度维持长达120小时。